Midkine Role With Deregulated Oxidative and Immune Milieu in Induction of Preeclampsia
NCT ID: NCT06329284
Last Updated: 2024-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2023-01-01
2023-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Midkine (MDK) is a multifunctional protein that plays a unique role in the development of hypertension (HTN), via its proatherogenic effect and induction of overexpression of angiotensin converting enzyme. Oxidative stress (OS) upregulates the expression of MDK and MDK induces propagation of neoangiogenesis and acts as chemotactic for neutrophils.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Serpin C and Soluble Fms-like Tyrosine Kinase-1 Levels in Normotensive Pregnant Women May Predict the Development of Preeclampsia
NCT06214702
Assessment of Oxidative Stress Contents in Jordanian Pregnant Women With Preeclampsia
NCT07119034
The Role of Pentraxin 3 and Cathepsin B Levels in Preeclamptic Pregnancy
NCT05924061
Extracellular Matrix Remodeling of the Umbilical Cord and Placenta in Preeclampsia
NCT01931891
Molecular Study of the Maternal-fetal Interface in Preeclampsia.
NCT06232668
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Serum Midkine
ELISA
ELISA estimation of serum Midkine, tumor necrosis factor Alfa, superoxide dismutase, malondialdehyde, placental growth factor and placental soluble fms-like tyrosine kinase 1
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ELISA
ELISA estimation of serum Midkine, tumor necrosis factor Alfa, superoxide dismutase, malondialdehyde, placental growth factor and placental soluble fms-like tyrosine kinase 1
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Had manifest essential hypertension, Diabetes Mellitus or chronic kidney diseases;
* Had multiple gestational sacs, morbid obesity with Body Mass Index at time of pregnancy diagnosis over 35 kg/m2;
* Had genetic disorders, coagulopathy, autoimmune diseases or maintained on immunosuppressive therapy.
21 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shereen Naguib
Lecturer of Obstetrics & Gynecology, Faculty of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banha University
Banhā, El- Qalyobia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC 31.1.2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.